OPTIMAL phase III trial
PFS was significantly longer in erlotinib-treated Chinese patients with EGFR Mut+ NSCLC compared with that of patients treated with standard chemotherapy. Erlotinib was also better tolerated.1,2
Patients receiving erlotinib had longer PFS than patients receiving chemotherapy.
Patients treated with erlotinib experienced fewer treatment related severe AEs, fewer grade 3/4 AEs and fewer dose reductions due to AEs than patients treated with chemotherapy.
Please click here for further safety data
- OPTIMAL: summary of safety data1
- OPTIMAL: most common adverse events reported in 3% of patients or more in either treatment group1